Seelos therapeutics receives an acknowledgement letter of a clinical trial notification from the australian government department of health therapeutic goods administration for a pilot study of sls-005 in alzheimer's disease

New york, march 8, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received an acknowledgement letter of a clinical trial notification (ctn) from the australian government department of health therapeutic goods administration (tga) for a pilot study of sls-005 (trehalose injection, 90.5 mg/ml for intravenous infusion) for the treatment of patients with alzheimer's disease.   "trehalose's activity in alzheimer's disease is unique as it inhibits both the beta-amyloid pathology and tau aggregates in preclinical rodent models.
SEEL Ratings Summary
SEEL Quant Ranking